- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Kadmon Holdings announced the closing of a public offering for gross proceeds of approximately $80.4 million.
Kadmon Holdings (NYSE:KDMN) announced the closing of a public offering for gross proceeds of approximately $80.4 million.
As quoted in the press release:
Proceeds from the offerings will be used to advance the development of Kadmon’s product candidates, including KD025, the company’s lead Rho-associated coiled-coil kinase (ROCK) inhibitor, which is currently in Phase 2 clinical studies in autoimmune and fibrotic disease indications.
“This financing is transformative for Kadmon and provides the resources to advance our various programs, in particular KD025 in chronic graft-versus-host disease and idiopathic pulmonary fibrosis, through multiple key inflection points,” said Harlan W. Waksal, M.D., President and CEO at Kadmon. “In parallel, we will continue to build our portfolio of preclinical ROCK inhibitors for the treatment of autoimmune, fibrotic and neurodegenerative diseases.”
Click here to read the full press release.
Source: www.businesswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.